Develops molecular diagnostic tests for cancer patients.
Jun 2026Revenue $562M/yrExpenses $456M/yr
Reached break-even Nov 2024
Figures by year
When did Veracyte become profitable?
Its revenue passed its expenses in Nov 2024. In the 12 months to Jun 2026, revenue was $562M and expenses $456M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $517M | $459M | $57.8M |
| Dec 2024 | $446M | $430M | $16.1M |
| Dec 2023 | $361M | $447M | −$85.8M |
| Dec 2022 | $297M | $338M | −$41.1M |
| Dec 2021 | $220M | $301M | −$81.9M |
| Dec 2020 | $117M | $153M | −$35.4M |
| Dec 2019 | $120M | $135M | −$15.1M |
| Dec 2018 | $92.0M | $114M | −$22.2M |
| Dec 2017 | $72.0M | $98.5M | −$26.5M |
| Dec 2016 | $65.1M | $93.9M | −$28.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.